Highest-materiality recent filing
Amneal shareholders approve all proposals at 2026 annual meeting
All 10 director nominees elected; Chintu Patel received ~270.4M votes (highest).
Amneal Q1 2026 net revenue $723M (+4% YoY), GAAP net income $62M, adj. diluted EPS $0.27
Net revenue $723M (+4% YoY); GAAP net income $62M vs. $12M in Q1 2025; diluted EPS $0.19.
Amneal acquires Kashiv BioSciences for $750M upfront; raises FY2026 guidance on strong Q1
Acquisition of Kashiv: $375M cash + $375M equity (28.9M shares) at close; up to $350M regulatory milestones plus royalties.
Amneal reports Q4 2025 net revenue $814M (+11% YoY); FY25 rev $3.02B; 2026 guidance $3.05-$3.15B
Q4 2025 net revenue $814M (+11% YoY); GAAP net income $35M; diluted EPS $0.11.
Amneal reprices $2.1B term loan, margin cut 50 bps, saving ~$11M/year
Repricing amendment reduces interest rate margin by 50 bps to SOFR+3.00% or Base Rate+2.00%.
Amneal Pharmaceuticals makes effective opioid settlement with states and subdivisions
Amneal determined to make effective its Nationwide Opioids Settlement Agreement on Jan 29, 2026, with sufficient state and subdivision participation.
Amneal expects to meet or exceed FY2025 guidance; net leverage improves to 3.6x
Net revenue guidance $3.0B-$3.1B; Adj EBITDA $675M-$685M; Adj diluted EPS $0.75-$0.80.
Amneal Q3 revenue $785M (+12% YoY); GAAP EPS $0.01, adj. EPS $0.17; updated FY guidance
Net revenue $785M (+12% YoY); GAAP net income $2M vs loss of $0.2M; diluted EPS $0.01.
Amneal board adopts annual say-on-pay votes following stockholder preference
Stockholders recommended annual frequency for advisory say-on-pay votes; board agreed on August 5, 2025.
Amneal Q2: rev $725M (+3%), adj EBITDA $184M (+13%), raises FY25 guidance, refi debt
Q2 net revenue $725M, up 3% YoY; GAAP net income $22M vs $6M in Q2 2024.
Amneal completes $2.7B refinancing: $2.1B term loan and $600M notes
Borrowed $2.1B of new seven-year term B loans due Aug 2032; margin SOFR+3.50% or base+2.50%.
Amneal prices $600M 6.875% senior secured notes due 2032, upsizes term loan to $2.1B
$600M notes priced at par with 6.875% coupon, due 2032; downsized from $750M due to term loan increase.
Amneal seeks $1.8B new term loans and $750M notes to refinance debt
Amneal subsidiary seeks $1.8B in new seven-year term B loans to refinance existing term loans.
Amneal prelim Q2 revenue $720M-$730M, adj EBITDA $180M-$185M; director resigns
Net revenue $720M-$730M (+3% YoY); income before taxes $45M-$56M vs $20M in Q2 2024.
All Amneal director nominees elected, say-on-pay approved at annual meeting
11 directors elected with overwhelming support; Paul Meister received lowest 'For' count at 239.8M shares.
Amneal Q1 revenue $695M (+5% YoY), net income $12M vs loss, adj EPS $0.21 (+50%), reaffirms guidance
Net revenue $695M, up 5% YoY; GAAP net income $12M vs $92M loss in Q1 2024; diluted EPS $0.04 vs ($0.30).
Amneal promotes Jason Daly to EVP, Chief Legal Officer; base salary $575k
Promoted from SVP to EVP, Chief Legal Officer & Corporate Secretary, effective March 1, 2025.
Amneal reports Q4 revenue $731M (+18% YoY), FY24 revenue $2.79B (+17%); guides FY25 $3.0-3.1B
Q4 2024 GAAP net loss $31M ($0.10 diluted loss per share); adjusted net income $40M, adjusted EBITDA $155M.
Amneal expects to meet or exceed 2024 full-year guidance; net leverage ~4x
Expects to meet net revenue ($2.70-2.80B), adjusted EBITDA ($610-630M), and adjusted diluted EPS ($0.57-0.63).
Amneal Q3 net revenue up 13% to $702M; adjusted EBITDA $158M, guidance affirmed
Net revenue $702M (+13% YoY); GAAP net loss ~$0.2M vs prior year net income of $10M.
Amneal Q3 revenue up 13% to $702M; GAAP net loss $0.2M, adjusted EPS $0.16; affirms guidance
Revenue $702M (+13% YoY); adjusted EBITDA $158M (+2% YoY); adjusted diluted EPS $0.16 vs $0.19 YoY.
Amneal and Metsera partner on obesity drug portfolio; new India facilities cost $150-200M
Amneal to build two manufacturing facilities in India for peptide synthesis and sterile fill-finish; net cost $150-200M over 4-5 years.
Amneal beats Q2 estimates, raises FY guidance; FDA approves CREXONT for Parkinson's
Q2 net revenue $702M (+17% YoY); GAAP net income $6M ($0.02 diluted EPS).
Amneal shareholders elect all 11 directors, approve say-on-pay at annual meeting
All 11 director nominees elected; votes ranged from 238.7M (Meister) to 254.4M (Yanai) for.
Amneal Q1 revenue $659M (+18% YoY); GAAP net loss $92M on $94M opioid charge
Net revenue $659M (+18% YoY); Generics +14%, Specialty +15%, AvKARE +33%.
The Agreement provides that, as of the Effective Date, Mr. Daly will be employed as the Company’s Executive Vice President, Chief Legal Officer & Corporate Secretary at an annual base salary of $575,000.
Max materiality 0.90 · Median 0.70 · Most common event earnings